This success was further enhanced when combined with immune checkpoint inhibitors, leading to pronounced effects in animal models. The research driving InProTher's work leverages the expertise of Associate Professor Peter Johannes Holst and his team, as well as international collaborators.
The company has recently received a significant boost through a €6.00M Seed Round investment on 24 May 2023, with funding from The European Innovation Council and SeedFolio. InProTher's focus on leveraging pre-clinical success and its collaboration with renowned experts make it a compelling prospect in the biotechnology and healthcare industries.
InProTher
InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst.
Founded 2018
2-10 employees
Seed
Total: $8.50M
Biotechnology, Health Care
General Information
Get notified when InProTher moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track InProTher
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Biotechnology
About InProTher
Taxonomy: Cancer immunotherapy, Pre-clinical models, Advanced therapies, Immune checkpoint inhibitors, Tumor immunity, Research collaboration, Cancer therapy development, Immunotherapy success, Professor Holst, Associate Professor Holst, Cancer research, Cancer treatment innovations
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Seed Round | •••••• | 2 |
|
24 May 2023 |
| Grant | •••••• | 1 |
|
15 Oct 2021 |
| Venture Round | •••••• | 1 |
|
16 Jun 2021 |
InProTher Alternatives & Competitors
InProTher vs
BriaCell Therapeutics Corp.
United States
Developing Novel Therapies to Destroy Cancer
Post Ipo Equity
20 employees
Biotechnology, Health Care
InProTher vs
Seven and Eight Biopharmaceuticals Inc.
United States
Seven and Eight Biopharmaceuticals Inc. is at the forefront of immuno-oncology innovations
2 employees
Biopharma, Biotechnology
InProTher vs
Pioneering the future of cancer immunotherapy with CAR-T cell advancements from academic innovation.
Series C
Biotechnology
FAQ About InProTher
InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst.
InProTher was founded in 2018.
InProTher operates in the following industries: Biotechnology, Health Care.
InProTher has approximately 2-10 employees.
InProTher has completed 3 funding rounds, raising a total of $8.50M. The latest funding stage is Seed.
Top alternatives and competitors to InProTher include BriaCell Therapeutics Corp., Seven and Eight Biopharmaceuticals Inc., Noile-Immune Biotech, UbiVac, Checkmate Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
InProTher and BriaCell Therapeutics Corp. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors InProTher and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.